公开(公告)号：US20150247873A1

公开(公告)日：2015-09-03

申请号：US14712422

申请日：2015-05-14

申请人： ZORA BIOSCIENCES OY

发明人： Reijo LAAKSONEN ,  Kim EKROOS ,  Reini HURME ,  Riika KATAINEN

IPC分类号： G01N33/92

CPC分类号： G01N33/92 ,  A61K31/366 ,  A61K31/397 ,  G01N2405/04 ,  G01N2570/00 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52

摘要： The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

摘要翻译： 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来诊断和/或预测动脉粥样硬化或CVD的方法及其用途，并且鉴定了特异性的特异性脂质标记物 并且在检测和预测动脉粥样硬化和CVD时比目前使用的临床标志物敏感。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗动脉粥样硬化或CVD的用途。 本发明还涉及包含脂质和/或其抗体的试剂盒，用于预测和/或诊断动脉粥样硬化或CVD。

公开(公告)号：US20220003791A1

公开(公告)日：2022-01-06

申请号：US17295139

申请日：2019-12-06

申请人： Zora Biosciences OY

发明人： Mika HILVO ,  Reijo LAAKSONEN

IPC分类号： G01N33/92

摘要： The present disclosure relates to methods and uses involving the determination of lipid concentrations in order to diagnose, predict, prevent and/or treat one or more cardiovascular events in a subject. The methods include analyzing lipid concentrations of a sample from the subject and comparing them to a control.

公开(公告)号：US20240183866A1

公开(公告)日：2024-06-06

申请号：US18441255

申请日：2024-02-14

申请人： ZORA BIOSCIENCES, OY

发明人： Reijo LAAKSONEN

IPC分类号： G01N33/92 ,  A61K31/164 ,  C07B59/00

CPC分类号： G01N33/92 ,  A61K31/164 ,  C07B59/001 ,  G01N2405/08 ,  G01N2458/15 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

摘要： The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

公开(公告)号：US20200348316A1

公开(公告)日：2020-11-05

申请号：US16762612

申请日：2018-11-20

申请人： Zora Biosciences Oy ,  BAKER HEART AND DIABETES INSTITUTE

发明人： Kevin HUYNH ,  Dianna MAGLIANO ,  Jonathan SHAW ,  Mika HILVO ,  Reijo LAAKSONEN ,  Peter MEIKLE

IPC分类号： G01N33/68 ,  G01N33/92 ,  G16H20/10 ,  G16H10/60 ,  G16H50/20 ,  G16H50/30

摘要： The present disclosure is related to the field of diabetes diagnostics. It introduces novel biomarkers that can be used to predict diabetes and detect presence of the disease. In addition, novel fatty acid biomarkers are presented.